Menu
Back to User profile » Dr Alexa B. Schrock
Papers published by Dr Alexa B. Schrock:
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM
Lung Cancer: Targets and Therapy 2020, 11:33-39
Published Date: 17 April 2020
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
Zhu VW, Schrock AB, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2019, 10:21-26
Published Date: 12 March 2019
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
Zhu VW, Schrock AB, Bosemani T, Benn BS, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2018, 9:111-116
Published Date: 8 November 2018
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
Parikh AR, Ali SM, Schrock AB, Albacker LA, Miller VA, Stephens PJ, Crilley P, Markman M
Lung Cancer: Targets and Therapy 2018, 9:45-47
Published Date: 18 May 2018
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
Klempner SJ, Mehta P, Schrock AB, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2017, 8:241-247
Published Date: 6 December 2017